Yongfei Wang

Dr. Yongfei Wang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
MSMing Shen
Ming Shen
QZQilin Zhang
Qilin Zhang
WLWenjuan Liu
Wenjuan Liu
MWMeng Wang
Meng Wang
JZJingjing Zhu
Jingjing Zhu
YWYongfei Wang
Yongfei Wang

6 October 2020 in Pituitary
Verified
Journal Article
Closed access
PDF file
NQNidan Qiao
Nidan Qiao
MSMing Shen
Ming Shen
WHWenqiang He
Wenqiang He
MHMin He
Min He
ZZZhaoyun Zhang
Zhaoyun Zhang
YZYao Zhao
Yao Zhao

16 September 2015 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
ZMZengyi Ma
Zengyi Ma
WHWenqiang He
Wenqiang He
YZYao Zhao
Yao Zhao
JYJie Yuan
Jie Yuan
QZQilin Zhang
Qilin Zhang
YWYongfei Wang
Yongfei Wang

1 January 2019 in World Neurosurgery
Verified
Journal Article
Closed access
XLXiaoqing Li
Xiaoqing Li
WWWei Wu
Wei Wu
QMQing Miao
Qing Miao
MHMin He
Min He
SZShuo Zhang
Shuo Zhang
HYHongying Ye
Hongying Ye

1 January 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
WRWenting Rui
Wenting Rui
YWYue Wu
Yue Wu
ZMZengyi Ma
Zengyi Ma
YWYongfei Wang
Yongfei Wang
YWYin Wang
Yin Wang
ZYZhenwei Yao
Zhenwei Yao

2 January 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ZCZhengyuan Chen
Zhengyuan Chen
XSXuefei Shou
Xuefei Shou
LJLijin Ji
Lijin Ji
HCHaixia Cheng
Haixia Cheng
MSMing Shen
Ming Shen
YWYongfei Wang
Yongfei Wang
Objective To review experience regarding the treatment of prolactinomas by endoscopic endonasal surgery focusing on the association between presurgical dopamine agonist (DA) treatment and perioperative outcomes, surgical morbidities, endocrine outcomes, and pathological characteristics. Methods A single-center series of 290 cases was analyzed retrospectively and clinical data were collected. Intratumoral collagen content was assessed by Masson trichrome staining. Results Tenacious tumor consistency (27.8% vs 9.8%, P < .001) was more common in DA-pretreated patients compared with patients who underwent initial surgery. Moreover, DA-pretreated macroadenomas presented more intraoperative blood loss (200 [100-400] mL vs 175 [100-300] mL; P = .014), longer surgical duration (177 ± 95 minutes vs 154 ± 57 minutes; P = .043), and more surgical morbidities (19.4% vs 8.9%; P = .034). Additionally, DA-pretreated macroadenomas presented a higher collagen volume fraction than that of the initial surgery group (23.6 ± 2.2% vs 13.2 ± 2.1%; P = .001). Correlation analysis revealed a close correlation between collagen volume fraction and the cumulative dose of bromocriptine (BRC) in macroadenomas (r = 0.438, P < .001). Regarding endocrine outcomes, DA-pretreated microadenomas showed a lower proportion of initial remission compared with patients who underwent initial surgery (86.7% vs 100%, P = .047). Conclusion This study described increased surgical difficulty and inferior endocrine outcomes associated with tumor fibrosis secondary to presurgical BRC treatment in prolactinomas. Neurosurgeons should note that presurgical BRC treatment may render subsequent surgery more challenging.